Journal article

Callosal thickness profiles for prognosticating conversion from mild cognitive impairment to Alzheimer's disease: A classification approach

Chris Adamson, Richard Beare, Gareth Ball, Mark Walterfang, Marc Seal

Brain and Behavior | WILEY | Published : 2018


Awarded by Department of Defense

Awarded by National Institutes of Health

Funding Acknowledgements

Department of Defense, Grant/Award Number: W81XWH-12-2-0012; National Institute on Aging; National Institute of Biomedical Imaging and Bioengineering; AbbVie; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai; Elan; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd; Genentech; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson; Lumosity; Lundbeck; Merck; Meso Scale Diagnostics; NeuroRx Research; Neurotrack Technologies; Novartis; Pharmaceuticals; Pfizer; Piramal Imaging; Servier; Takeda Pharmaceutical Company; Transition Therapeutics; Health Research; National Institutes of Health, Grant/Award Number: U01 AG024904; Northern California Institute for Research and Education; University of Southern California